With orforglipron, its a newer, non-peptide version of a GLP-1, so we dont yet have the same depth of safety data as the injectables. A spokesperson for the Department of Health and Human Services, which oversees the FDA, didnt immediately respond to a request for comment
These particular segments will compose the PDF template that you'll be creating: In the Please indicate which drug and, QuantityRequested, for, days supply, Other MedicationsTherapies tried, Prescriber Signature, Office Contact Name, Date, Phone Number, and Based upon each patients area, note your information
Acta Cytol
However, there are studies and case reports that touch on musculoskeletal discomfort as a possible issue for some patients
Meng W, Xue S, Chen Y